|
Carmona-Bayonas A, Alvarez-Escola C, Ballester Navarro I, Hernando Cubero J, Mangas Cruz MA, Garcia-Centeno R, Iglesias C, Garcia-Donas J, Picon MJ, Paja M, Gonzalez Batanero L, Garcia L, Alonso Gordoa T, Lopez C, Hanzu F, Martinez-Trufero J, Febrero B, Saiz-Lopez P, Blanco Carrera C, Ramon Y Cajal T, Veiguela B, Gressani O, Valdes N, Jimenez-Fonseca P. Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry. J Clin Endocrinol Metab. 2025 Oct 16;110(11):3155-3167. doi: 10.1210/clinem/dgaf082. PubMed PMID: 39988973.
AÑO: 2025; IF: 5.1
|
39988973
|
Jimenez-Fonseca P, Alvarez-Escola C, Ballester Navarro I, Hernando Cubero J, Gonzalez Fernandez L, Mangas Cruz MA, Iglesias C, Garcia-Donas J, Picon MJ, Paja M, Gonzalez Batanero L, Garcia L, Molina J, Jimeno Mate R, Aller J, Romero MDCT, Cardenas Salas J, Gutierrez-Buey G, Egana Zunzunegui N, Navarro M, Lecumberri MJ, Valdes N, Carmona-Bayonas A. External validation of the S-GRAS score for predicting recurrence in patients with adrenocortical carcinoma: implications for adjuvant mitotane therapy. Eur J Endocrinol. 2025 Jul 31;193(2):320-328. doi: 10.1093/ejendo/lvaf171. PubMed PMID: 40810251.
AÑO: 2025; IF: 5.2
|